Pfizer Buys Seagen In $43B Enterprise Value Deal
Pfizer said Monday it has entered into an agreement to acquire global cancer biotechnology company Seagen for $229 in cash per Seagen share, giving the transaction a total enterprise value of...To view the full article, register now.
Already a subscriber? Click here to view full article